Tillkännagivande • Dec 18

Corestemchemon Advances Toward Als Stem Cell Commercialization with Regulatory Progress in Korea and Nsf-Backed U.S. Expansion

CorestemChemon is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supported regenerative medicine ecosystem in the United States, secured commercialization capital, and a sizable open-market share purchase by the CEO. In Korea, Neuronata-R is undergoing a product license modification review by the Ministry of Food and Drug Safety (MFDS). Following mixed efficacy results in the overall patient population in the Phase 3 ALSUMMIT trial, CorestemChemon refined its regulatory strategy to focus on a clinically defined " slow progressor" subgroup. Post-hoc analyses in this subgroup showed clinically meaningful and internally consistent signals, including maintenance of ALS Functional Rating Scale-Revised (ALSFRS-R) scores, stabilization of slow vital capacity (SVC), and favorable trends in neurofilament light chain (NfL) biomarkers. The company believes these findings have supported a more structured and focused regulatory dialogue with the MFDS. The company expects this precision-targeted approach to further clarify the domestic regulatory pathway, while preserving the option for initial commercialization upon potential approval. A favorable MFDS decision would enable domestic market entry and generation of real-world evidence (RWE), which could support future global regulatory strategies. The company expects a final regulatory decision in Korea before the first quarter of 2026. CorestemChemon has been selected to join the Piedmont Triad Regenerative Medicine Innovation Engine, a U.S. regional innovation cluster supported by the National Science Foundation (NSF). The company stated that it is the first Korean biotechnology firm to be included in an NSF-backed regenerative medicine ecosystem. The selection was initiated by the Wake Forest Institute for Regenerative Medicine (WFIRM), which cited the scientific robustness of Neuronata-R's Phase 3 clinical dataset and the consistency observed in long-term real-world follow-up data. Participants in the NSF Engine is expected to provide access to translational research capabilities, manufacturing resources, and a broader regulatory network. To align more closely with this ecosystem, CorestemChemon plans to relocate its U.S. subsidiary to North Carolina. The company intends to leverage the cluster as a platform for regulatory engagement with the U.S. Food and Drug Administration (FDA), targeting submission of a Biologics License Application (BLA) in the third quarter of 2026. Commercialization Funding and Financial Position: To support commercialization readiness following potential domestic approval, CorestemChemon recently completed a rights offering, raising KRW 26.1 billion in operating capital (approximately USD 17.8 million, based on recent exchange rates). The proceeds are allocated to upgrading production facilities, establishing commercial-scale manufacturing systems, and preparing for both domestic and global regulatory processes. The company expects the capital raise to strengthen its financial position and reduce execution risk associated with manufacturing scale-up and regulatory preparation, while addressing near-term funding concerns. In a move widely interpreted as reinforcing market confidence, CEO Yang Gil-ahn recently executed a large-scale open-market share purchase. Over a two-week period, he acquired more than one million shares, representing an investment of approximately KRW 1.7 billion (approximately USD 1.2 million, based on recent exchange rate). The purchase coincided with the submission of supplementary regulatory materials to the MFDS and is viewed as a signal of management's conviction at a key regulatory inflection point. Following the transaction, the combined ownership stake of the controlling shareholder group increased to 10.32%, further strengthening alignment between management and shareholders.

Tillkännagivande • Sep 18

Neuronata- Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway

CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel), an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), at the PACTALS 2025 congress in Melbourne, Australia. The first session, chaired by Professor Seung-Hyun Kim of Hanyang University Hospital — a global leader in stem cell-based ALS research — brought together a panel of seven distinguished ALS experts from six countries. As part of the panel, Dr. Ryung-A Lee (Head of R&D Innovation, CorestemChemon) introduced the company and shared a brief overview of the Phase 3 trial results. In the second session, the full Phase 3 clinical trial (ALSUMMIT trial) results were formally presented by Professor Ki-Uk Oh (Department of Neurology, Advanced Regenerative Medicine Center, Hanyang University Hospital, and principal investigator of the ALSUMMIT trial). Subgroup Analysis Demonstrates Statistically Significant Benefit: While the overall trial did not meet its primary and secondary endpoints, Neuronata-R® showed meaningful efficacy in patients with slower disease progression. At 12 months, participants in this subgroup receiving Neuronata-R achieved: ALSFRS-R (functional rating scale): 31.2 vs. 26.4 in placebo (p=0.001), CAFS (Combined Assessment of Function and Survival): 20.95 and 24.78 vs. 17.92 in placebo (p=0.024; p=0.041), SVC (slow vital capacity, respiratory function): 62.2% vs. 50.6% in placebo (p=0.017, Study Group 2). These findings confirm Neuronata-R's potential to preserve function and respiratory capacity in ALS — outcomes directly linked to quality of life and survival. Biomarker Data Underscore Neuroprotective Effect: Biomarker analysis revealed sustained reductions in neurofilament light chain (NfL) and MCP-1, indicating a strong link between neuroprotection and clinical outcomes. This strengthens the case for biomarker-guided patient stratification and a precision-medicine strategy in ALS drug development, reflecting the evolving global regulatory landscape. Regulatory Pathway Toward Accelerated Approval: CorestemChemon stated that the PACTALS 2025 results mark an important step for regulatory discussions. The company plans to request a Type-C meeting with the U.S. Food and Drug Administration (FDA) in Fourth Quarter 2025 to discuss the dataset and biomarker-driven subgroup efficacy. Based on this discussion, CorestemChemon plans to submit a Biologics License Application (BLA) within 2026, aiming to pursue an accelerated approval pathway aligned with precedents in ALS, including FDA's decision on Tofersen.

VD-lön i procent	n/a
Anställning som VD	no data
Ägande av VD	8.0%
Ledningens genomsnittliga anställningstid	inga uppgifter
Styrelsens genomsnittliga mandatperiod	inga uppgifter

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/09/15 18:16
Aktiekurs vid dagens slut	2026/09/15 00:00
Intäkter	2026/06/30
Årlig intjäning	2025/12/31

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

Analytiker	Institution
Byung Hwa Han	Eugene Investment & Securities Co Ltd.
Jiyong Lee	Shinhan Investment Corp.
Choongwoo Seo	SK Securities Co., Ltd.

CORESTEMCHEMON Förvaltning

Förvaltning kriterier kontrolleras 0/4

Viktig information

Senaste uppdateringar av ledningen

CORESTEMCHEMON Inc., Annual General Meeting, Mar 27, 2026

CORESTEMCHEMON Inc., Annual General Meeting, Mar 28, 2025

Recent updates

New minor risk - Market cap size

New major risk - Financial position

CORESTEMCHEMON Inc., Annual General Meeting, Mar 27, 2026

CORESTEMCHEMON Inc. (KOSDAQ:166480) Shares Fly 46% But Investors Aren't Buying For Growth

Corestemchemon Advances Toward Als Stem Cell Commercialization with Regulatory Progress in Korea and Nsf-Backed U.S. Expansion

Investors Don't See Light At End Of CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Tunnel

New major risk - Shareholder dilution

CORESTEMCHEMON Inc. has completed a Follow-on Equity Offering in the amount of KRW 26.14 billion.

Neuronata- Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway

CORESTEMCHEMON Inc. has filed a Follow-on Equity Offering in the amount of KRW 37.8 billion.

Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price Plunge

New minor risk - Share price stability

Corestemchemon Announces Neuronata-R®? Stem Cell Therapy Shows Promise in Als Phase 3 Subgroup Analysis, Moves Toward Fda Accelerated Approval

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is Lacking

CORESTEMCHEMON Inc., Annual General Meeting, Mar 28, 2025

Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?

New minor risk - Market cap size

New major risk - Share price stability

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

New major risk - Financial data availability

Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling You

New major risk - Financial position

New minor risk - Share price stability

CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry

Third quarter 2023 earnings released: ₩219 loss per share (vs ₩362 loss in 3Q 2022)

Second quarter 2023 earnings released: ₩115 loss per share (vs ₩237 profit in 2Q 2022)

CORESTEMCHEMON Inc. announced that it has received KRW 32.31145 billion in funding from a group of investors

CORESTEMCHEMON Inc. announced that it expects to receive KRW 21.5 billion in funding from a group of investors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

New 90-day low: ₩19,150

If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns

Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

New 90-day low: ₩20,500

VD OCH KONCERNCHEF

Företagsanalys och finansiella data Status

Datakällor

Analysmodell och snöflinga

Industri- och sektormått

Källor för analytiker